While World Lung Cancer Day was recognized on August 1, the urgent need to raise global awareness and accelerate the search for a cure remains year-round. With this ongoing mission, the Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC) are awarding $200,000 each to two of the field's most promising young scientists. This investment addresses a critical reality: brilliant research ideas often stall not from lack of vision but from lack of resources. By providing this funding, LCFA and IASLC are ensuring these researchers have the momentum to turn today's innovative ideas into tomorrow's life-saving breakthroughs.
The two funded projects tackle two of the toughest questions in the fight against lung cancer: how to catch it earlier and how to stop it from outsmarting treatments. Both are essential to helping patients live longer, better lives. The Early Career Researcher (ECR) grant program gives emerging scientists the fuel to secure major independent research awards, which can be launching pads for careers. These researchers aren't just studying the future of lung cancer science; they're building it.
This year's recipients, selected for their proposal originality and potential to change patient outcomes, are Dr. Jared Mayers of Fred Hutch Cancer Center and Dr. Jaime L. Schneider of Dana-Farber Cancer Institute. The timing is urgent: competition for research dollars grows fiercer every year, even as lung cancer claims a life in the United States every 4.2 minutes. When bold early-career investigators receive real, independent funding, their most innovative ideas don't stall on a shelf. They move forward and change what's possible in oncology.
"Supporting early-career investigators is not just a strategic priority. It is a necessity for the future of oncology," said Kim Norris, co-founder and president of LCFA. "By investing in these researchers, we are accelerating the pace of discovery and ensuring that promising ideas in metabolic tracking and drug resistance can move from the laboratory to the clinic, where they are needed most."
Dr. Mayers is investigating how naturally occurring bacteria in the lungs may shape the development of lung cancer. Because these bacteria exist in tiny amounts, they've been nearly impossible to study. Dr. Mayers is building tools to see them by developing highly sensitive techniques to capture and analyze how these microbes behave inside lung tissue. By mapping how they contribute to cancer, his team hopes to uncover new ways to stop the disease before it starts. "We don't get new drugs, we don't get new therapies, we don't get longer lives, better quality lives, more time with family unless we invest in the upfront groundwork," he said.
Dr. Schneider is decoding how lung cancer cells learn to survive and keep growing after treatment. Her focus is on how these cells manage their energy and where that system has a weak link worth exploiting. Her goal is to design new, more effective therapies that keep cancer from adapting, offering better and longer-lasting options for patients whose disease has grown resistant to standard chemotherapy and targeted treatments. "I was simply blown away by the tremendous arsenal of new drugs that had just come out that were really changing patient lives," she said, describing what drew her to thoracic oncology.
LCFA and IASLC invite the community to go behind the science with all of the ECR grant recipients. Visit these researchers' profiles and video insights into their lab work at LCFA's Meet the Researcher.
LCFA's Early Career Research Grant Program has a remarkable "multiplier effect" currently at 13X return on investment. By providing the first spark for transformative science, the program has awarded 25 grants totaling $4.6 million, funding that has since grown into more than $50 million in additional grants from other organizations building on LCFA-supported research. That track record means Dr. Mayers and Dr. Schneider aren't just receiving funding; they're gaining the foundation to secure major, long-term support their work deserves.
This $400,000 investment underscores LCFA and IASLC's ongoing commitment to accelerating the pace of discovery for patients everywhere. For more resources and information about lung cancer, visit lcfamerica.org.
